Literature DB >> 20839162

[Knowledge about HBV, prevention behaviour and treatment adherence of patients with chronic hepatitis B in a large referral centre in Germany].

M Lutgehetmann1, F Meyer, T Volz, A W Lohse, C Fischer, M Dandri, Jörg Petersen.   

Abstract

BACKGROUND: The incidence of chronic hepatitis B in Germany is approximately 0.5 %. Data regarding knowledge about HBV, prevention behaviour and treatment adherence in patients with chronic HBV are scarce.
METHODS: In this prospective study 201 consecutive patients with CHB infection were studied from a large urban academic outpatient clinic at the University Medical Centre in Hamburg. Patients were interviewed with a questionnaire that contained 47 questions covering social demographic dates, knowledge about HBV, treatment adherence and prevention. The success rate of interviews was 100 % with free translation service offered.
RESULTS: 20.4 % of the CHB patients were born in Germany, but the majority of the patients were immigrants (80.6 %). 51 % of the patients had a good, 34 % a moderate and 15 % a poor knowledge about HBV. 89 % of the patients knew that HBV can be transmitted through blood contacts, but 34 % believed that inadequate hygienic conditions and 24 % that food products may transmit the virus. 96 % of the patients had knowledge about the existence of an HBV vaccine. Furthermore, 82 % considered a vaccination of all persons in the household important. Despite the knowledge of the existence and importance of a vaccine, only 61,7 % of the 300 affected children/siblings of HBV-positive family members were vaccinated. However, the child vaccination rate was significantly higher among patients with knowledge about the protective effect of the vaccine (p < 0.001), the free of charge vaccination program for children up to 18 years (p < 0.001) and higher school education (p < 0.001). Migrants with poor German language skills had lower knowledge scores (p < 0.001) and showed lower vaccination rates (p = 0.016) compared to immigrants with good German language skills. 43 % of all patients were treated with nucleot(s)ide analogues with a median treatment duration of 2 - 5 years. 65 % of these patients declared to never have missed a dose and 27 % missed less than one dose per month. 90 % of the patients tolerated the antiviral drugs very well and between patients with or without side effects there was no significant difference in quality of life.
CONCLUSION: Chronic hepatitis B in Germany is characterised by awareness problems and language barriers. More attention is needed for HBV-infected immigrants in the form of multilingual information about CHB and awareness campaigns. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2010        PMID: 20839162     DOI: 10.1055/s-0029-1245304

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  8 in total

1.  Barriers to Accessing Testing and Treatment for Chronic Hepatitis B in Afghan, Rohingyan, and South Sudanese Populations in Australia.

Authors:  Katherine Sievert; Paul O'Neill; Youlin Koh; Jia-Hui Lee; Anouk Dev; Suong Le
Journal:  J Immigr Minor Health       Date:  2018-02

Review 2.  Defining the determinants of vaccine uptake and undervaccination in migrant populations in Europe to improve routine and COVID-19 vaccine uptake: a systematic review.

Authors:  Alison F Crawshaw; Yasmin Farah; Anna Deal; Kieran Rustage; Sally E Hayward; Jessica Carter; Felicity Knights; Lucy P Goldsmith; Ines Campos-Matos; Fatima Wurie; Azeem Majeed; Helen Bedford; Alice S Forster; Sally Hargreaves
Journal:  Lancet Infect Dis       Date:  2022-04-13       Impact factor: 71.421

3.  Disease burden of chronic hepatitis B among immigrants in Canada.

Authors:  William W L Wong; Gloria Woo; E Jenny Heathcote; Murray Krahn
Journal:  Can J Gastroenterol       Date:  2013-03       Impact factor: 3.522

4.  Chronic Hepatitis Is Common and Often Untreated Among Children with Hepatitis B Infection in the United States and Canada.

Authors:  Simon C Ling; Hsing-Hua S Lin; Karen F Murray; Philip Rosenthal; Douglas Mogul; Norberto Rodriguez-Baez; Sarah Jane Schwarzenberg; Jeffrey Teckman; Kathleen B Schwarz
Journal:  J Pediatr       Date:  2021-05-20       Impact factor: 6.314

5.  Effect of a liver cancer education program on hepatitis B screening among Asian Americans in the Baltimore-Washington metropolitan area, 2009-2010.

Authors:  Hee-Soon Juon; Sunmin Lee; Carol Strong; Rajiv Rimal; Gregory D Kirk; Janice Bowie
Journal:  Prev Chronic Dis       Date:  2014-02-06       Impact factor: 2.830

6.  Estimating the scale of chronic hepatitis B virus infection among migrants in EU/EEA countries.

Authors:  Amena A Ahmad; Abby M Falla; Erika Duffell; Teymur Noori; Angela Bechini; Ralf Reintjes; Irene K Veldhuijzen
Journal:  BMC Infect Dis       Date:  2018-01-11       Impact factor: 3.090

Review 7.  Adherence to Nucleos(t)ide Analogue Therapies for Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis.

Authors:  Nathan Ford; Roz Scourse; Maud Lemoine; Yvan Hutin; Marc Bulterys; Zara Shubber; Dmytro Donchuk; Gilles Wandeler
Journal:  Hepatol Commun       Date:  2018-09-25

8.  The epidemiology of Hepatitis B, C and D in Germany: A scoping review.

Authors:  Gyde Steffen; Ida Sperle; Siv Aina Leendertz; Navina Sarma; Sandra Beermann; Roma Thamm; Viviane Bremer; Ruth Zimmermann; Sandra Dudareva
Journal:  PLoS One       Date:  2020-03-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.